Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6115868 | 0.75 | BTK (1.00) | BTK | |
| SCHEMBL27025879 | 0.74 | MET (0.48) | BTKCCNCCDK8 | |
| SCHEMBL10721733 | 0.72 | HPGD (0.95) | HPGDMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL25715682 | 0.71 | PIK3CD (0.48) | BTKHPGDKCNH2CCNCCDK8 | |
| SCHEMBL264516 | 0.70 | HPGD (0.76) | HPGDMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL6641990 | 0.70 | VNN1 (0.60) | HPGDMAPK1ALDH1A1AR | |
| SCHEMBL6173203 | 0.70 | HPGD (0.59) | HPGDALDH1A1 | |
| SCHEMBL7132525 | 0.70 | HPGD (1.00) | HPGDMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL27479149 | 0.70 | HPGD (1.00) | HPGDMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL6226277 | 0.69 | HPGD (0.60) | HPGDAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | BTK 1/4885HPGD 2184/4885MAPK1 1514/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | BTK 1/4885HPGD 2184/4885MAPK1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.